Drugs / AG-24322
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00147485 | Dec 2004 → Aug 2007 | non-Hodgkin lymphoma | Pfizer | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AG-24322 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545420 ↗ |
| Known as | AG-024322 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00147485 ↗ |
| Action | Inhibit | “An Inhibitor Of Cyclin-Dependent Kinase 1, 2 And 4” NCT00147485 ↗3“Cyclin-dependent kinase 4 inhibitor” CHEMBL3545420 ↗ “Cyclin-dependent kinase 2 inhibitor” CHEMBL3545420 ↗ “Cyclin-dependent kinase 1 inhibitor” CHEMBL3545420 ↗ |
| Modality | Small molecule | — CHEMBL3545420 ↗ |
| Route | Intravenous | “Administered Intravenously Daily For 5 Days Every 3 Weeks” NCT00147485 ↗ |
| Target | CDK1 | “Cyclin-dependent kinase 1 inhibitor” CHEMBL3545420 ↗ |
| Target | CDK2 | “Cyclin-dependent kinase 2 inhibitor” CHEMBL3545420 ↗ |
| Target | CDK4 | “Cyclin-dependent kinase 4 inhibitor” CHEMBL3545420 ↗ |